Financial Performance - The company's operating revenue for 2024 was ¥1,127,812,323.85, a decrease of 53.21% compared to ¥2,410,428,457.20 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥205,515,315.75, down 76.10% from ¥859,968,598.42 in 2023[21]. - The cash flow from operating activities for 2024 was ¥468,041,442.48, a decline of 47.29% compared to ¥888,024,961.36 in 2023[21]. - The basic earnings per share for 2024 was ¥0.3436, a decrease of 76.00% from ¥1.4316 in 2023[21]. - The total assets at the end of 2024 were ¥7,523,255,843.58, down 5.90% from ¥7,995,318,297.21 at the end of 2023[21]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, with a decrease of 84.12% to ¥120,390,566.59 in 2024 from ¥757,997,173.80 in 2023[21]. - The company is experiencing uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the last three accounting years[21]. - The company's total revenue for 2024 was approximately ¥1.13 billion, a decrease of 53.21% compared to ¥2.41 billion in 2023[47]. - Vaccine products accounted for 99.59% of total revenue in 2024, with a revenue of approximately ¥1.12 billion, down 53.34% from ¥2.41 billion in 2023[47]. - The influenza vaccine generated approximately ¥1.07 billion in revenue, representing 95.14% of total revenue from vaccine products, a decline of 55.34% year-over-year[48]. Market Conditions and Risks - The company's performance in 2024 significantly declined due to multiple factors, including a decrease in flu vaccine prices, fluctuations in vaccination rates, and a drop in market demand, with many vaccine companies reporting a decline of over 50% in their annual performance[5]. - Despite the challenging market environment, the company does not foresee significant risks to its ongoing operations, as there is no indication of overcapacity or sustained decline in the industry[5]. - The company has detailed potential risks in its report, which investors should review to understand the differences between plans, forecasts, and commitments[6]. - The overall trend of performance fluctuations aligns with the broader industry trends, as multiple domestic vaccine companies have experienced similar challenges[5]. - The competitive landscape for quadrivalent influenza vaccines is intensifying, with price reductions from multiple manufacturers potentially affecting market share and profitability[84]. - The company faces risks related to its product structure being relatively singular, with over 90% of revenue coming from influenza vaccines, which could impact profitability if market conditions change[82]. - The company faces risks in vaccine development due to lengthy approval processes and potential delays that could impact revenue generation[83]. Research and Development - The company continues to focus on research and development of new products and technologies to enhance its market position[5]. - The company is actively developing an mRNA vaccine research platform to prepare for future technological advancements in vaccine development[42]. - Research and development expenses increased by 78.51% to approximately ¥162.64 million, primarily due to increased clinical trial costs[56]. - The company has ongoing clinical research and registration for several vaccines, including a four-valent influenza vaccine and a rabies vaccine, with plans to expand its product pipeline[43]. - The company has established several core technology platforms to enhance vaccine research and production capabilities, aiming to mitigate product development risks[84]. Product Development and Market Strategy - The company has obtained drug registration certificates for various vaccines, including the quadrivalent influenza vaccine and the recombinant hepatitis B vaccine, establishing a strong position in the influenza vaccine sector[34]. - The company is preparing for production registration of the freeze-dried ACYW135 meningococcal polysaccharide vaccine, which has completed Phase III clinical trials[37]. - The company plans to reduce the price of the quadrivalent influenza vaccine by approximately 30% in June 2024 to enhance market competitiveness and accessibility[36]. - The company aims to improve the efficiency of fund utilization, achieving a usage rate of 56.31% for the raised funds[69]. - The company plans to enhance its marketing network to support the sales of existing products and the market introduction of new products, emphasizing the need for a more professional sales team[80]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[99]. Governance and Compliance - The company maintains a commitment to transparency and accuracy in its financial reporting, as affirmed by its board and management[5]. - The company has established a comprehensive internal control system and has maintained effective financial reporting internal controls with no significant deficiencies identified during the reporting period[133]. - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2024, with a standard unqualified opinion issued[137]. - The company has a strong governance structure, ensuring compliance with legal requirements and protecting shareholder interests[91]. - The company has implemented a transparent process for recommending board candidates, ensuring no interference in personnel decisions made by the board and shareholders[95]. Shareholder Engagement and Remuneration - The company plans to implement a stock repurchase program to stabilize its stock price within three years of its IPO, with a maximum repurchase amount not exceeding 30% of the previous year's audited net profit attributable to shareholders[156]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 192.77 million RMB[111]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation to company performance[131]. - The company ensured that minority shareholders had sufficient opportunities to express their opinions and that their rights were adequately protected[127]. - The company held its annual general meeting with an investor participation rate of 83.30% on April 19, 2024, and a temporary shareholders' meeting with a participation rate of 81.15% on August 9, 2024[97]. Social Responsibility and Community Engagement - The company emphasizes the integration of economic and social benefits, aiming for harmonious development with society while ensuring shareholder returns[144]. - The company actively engages in social responsibility initiatives, including targeted assistance in rural revitalization efforts[146]. - The company is committed to maintaining high standards in quality assurance and regulatory compliance in its operations[104]. - The company has pledged to continue its commitment to public welfare and community support as part of its operational strategy[144].

Financial Performance - The company expects a net profit for 2024 to be between 200 million and 250 million CNY, representing a decline of 70.93% to 76.74% compared to the previous year's profit of 859.9686 million CNY [3]. - The net profit after deducting non-recurring gains and losses is projected to be between 110 million and 160 million CNY, down 78.89% to 85.49% from last year's 757.9972 million CNY [3]. - Non-recurring gains and losses are expected to impact net profit by approximately 90 million CNY, primarily from investment income generated from idle funds [6]. Market and Sales Impact - The business development and profitability have been significantly impacted by changes in vaccination rates, declining market demand, and reduced sales [6]. - The company adjusted the price of its quadrivalent influenza vaccine by over 40% in June 2024 to enhance market competitiveness and accessibility [5]. Research and Development - The company maintains a high level of investment in R&D for innovative vaccines and gene-engineered vaccines, which has negatively affected net profit [6].

Financial Performance - The company's revenue for Q3 2024 was ¥921,834,062.89, representing a decrease of 41.23% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was ¥242,085,290.80, down 53.58% year-over-year[3]. - The basic earnings per share for Q3 2024 was ¥0.4042, a decline of 53.49% compared to the previous year[3]. - Total operating revenue for the current period is ¥957,363,018.62, a decrease of 44.4% compared to ¥1,718,267,831.09 in the previous period[20]. - Net profit for the current period is ¥267,359,727.86, a decrease of 57.5% compared to ¥629,714,837.48 in the previous period[21]. - Operating profit for the current period is ¥305,871,419.40, down 58.6% from ¥737,508,632.46 in the previous period[21]. - Basic earnings per share for the current period is ¥0.4463, down from ¥1.0495 in the previous period[22]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥7,641,648,782.70, a decrease of 4.42% from the end of the previous year[3]. - The total current assets decreased from 5,226,815,305.37 CNY at the beginning of the period to 4,631,880,229.62 CNY at the end of the period, representing a decline of approximately 11.4%[17]. - Total liabilities decreased from 1,732,226,370.79 CNY to 1,547,467,594.35 CNY, a reduction of approximately 10.7%[18]. - The company's total assets decreased from 7,995,318,297.21 CNY to 7,641,648,782.70 CNY, reflecting a decline of about 4.4%[18]. - The company's retained earnings decreased from 2,461,743,479.87 CNY to 2,369,094,207.73 CNY, a decrease of approximately 3.8%[19]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥350,644,555.60, down 28.24% year-over-year[3]. - Cash flow from operating activities for the current period is ¥350,644,555.60, a decrease of 28.3% compared to ¥488,668,014.32 in the previous period[23]. - The net cash flow from investing activities was -¥33,805,690.23, a 94.25% improvement from the previous period[8]. - The net cash flow from investing activities was -33,805,690.23 CNY, compared to -588,359,444.13 CNY in the previous period[24]. - The net increase in cash and cash equivalents was -109,728,909.46 CNY, compared to -224,261,096.50 CNY in the previous period[24]. - The ending balance of cash and cash equivalents was 531,251,202.49 CNY, up from 600,041,864.54 CNY at the beginning of the period[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,177[10]. - The largest shareholder, Hualan Biological Engineering, holds 67.38% of the shares, totaling 405,000,000 shares[10]. - The second-largest shareholder, Cyber Creator Limited, holds 8.98% of the shares, totaling 54,000,000 shares[10]. - The third-largest shareholder, Henan Huaying Enterprise Management Consulting Partnership, holds 4.99% of the shares, totaling 30,000,714 shares[10]. - The company has a total of 378,000 restricted shares due to executive lock-up[14]. - The report indicates that there are no preferred shareholders with voting rights[10]. - The top ten shareholders account for a significant portion of the total shareholding, with the largest three holding over 80% combined[10]. - The company has not disclosed any other relationships among the top ten shareholders, except for the relationship between Hualan Biological Engineering and Cyber Creator Limited[11]. - The report does not indicate any changes in the number of shares held by the top ten shareholders due to margin trading[12]. - The company has not issued any new shares during the reporting period[14]. Operational Adjustments - The company adjusted the prices of its quadrivalent influenza vaccines effective June 5, 2024, with adult prefilled 0.5ml at 88 CNY per dose, adult vial 0.5ml at 85 CNY per vial, and children's prefilled 0.25ml at 128 CNY per dose[15]. - The company aims to stimulate market demand for influenza vaccines through price adjustments, despite an expected short-term negative impact on sales revenue[15]. - The company plans to enhance internal cost control and improve sales volume to mitigate the pressure from price reductions[15]. - Research and development expenses for the current period are ¥80,510,272.88, an increase of 12.8% compared to ¥71,494,795.96 in the previous period[20]. - Sales expenses for the current period are ¥411,829,871.25, down 42% from ¥709,393,184.19 in the previous period[20]. - Tax expenses for the current period are ¥38,541,370.30, a decrease of 63.4% compared to ¥105,212,998.05 in the previous period[21]. Inventory Management - The company reported a significant increase in inventory, with a 40.56% rise to ¥243,832,814.78 compared to the beginning of the year[6]. - Inventory increased from 173,470,942.08 CNY to 243,832,814.78 CNY, marking an increase of about 40.5%[17].

证券代码：301207 证券简称：华兰疫苗 公告编号：2024-046 华兰生物疫苗股份有限公司 募集资金2024年半年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意华兰生物疫苗股份有限公司首次公开 发行股票注册的批复》（证监许可〔2022〕2 号），华兰生物疫苗股份有限公司（以 下简称"公司"）获准向社会公开发行人民币普通股（A 股）股票 4,001.00 万股，每 股面值人民币 1 元，发行价格为人民币 56.88 元/股，募集资金总额为人民币 2,275,768,800.00 元，扣除各项发行费用人民币 31,565,696.07 元（含税），实际募集 资金净额为人民币 2,244,203,103.93 元，上述募集资金已于 2022 年 2 月 14 日划至 公司指定账户。大华会计师事务所（特殊普通合伙）已于 2022 年 2 月 14 日对公司 首次公开发行股票的资金到位情况进行了审验，并出具了《验资报告》（大华验字 [2022]000066 号）。 截至 202 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 35,528,955.73, a decrease of 76.25% compared to CNY 149,603,691.12 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was CNY 25,274,437.06, down 76.65% from CNY 108,219,740.04 year-on-year[10]. - The net profit after deducting non-recurring gains and losses was CNY -21,321,549.76, a decline of 136.84% compared to CNY 57,878,391.61 in the previous year[10]. - The net cash flow from operating activities was CNY 250,319,631.54, a decrease of 35.68% from CNY 389,160,419.98 in the same period last year[10]. - The total assets at the end of the reporting period were CNY 7,259,126,454.97, down 9.21% from CNY 7,995,318,297.21 at the end of the previous year[10]. - The net assets attributable to shareholders of the listed company were CNY 5,915,537,307.14, a decrease of 5.55% from CNY 6,263,091,926.42 at the end of the previous year[10]. - The basic earnings per share were CNY 0.0421, down 76.66% from CNY 0.1804 in the same period last year[10]. - The diluted earnings per share were CNY 0.0421, a decrease of 76.62% compared to CNY 0.1801 in the previous year[10]. - The weighted average return on net assets was 0.41%, down 1.55% from 1.96% in the same period last year[10]. Cash Flow and Investments - The net cash flow from operating activities decreased by 35.68% to ¥250,319,631.54, mainly due to reduced sales collections[22]. - The company reported a significant increase in investment cash flow, amounting to ¥728,214,949.95, a 652.56% rise compared to a negative cash flow of ¥131,790,105.51 last year[22]. - The net increase in cash and cash equivalents was ¥621,513,313.65, reflecting a 363.06% increase from ¥134,217,314.45 in the previous year[22]. - The company’s cash and cash equivalents at the end of the reporting period reached ¥1,262,493,425.60, accounting for 17.39% of total assets, up from 8.02% last year[24]. - The company reported cash outflows from operating activities totaling CNY 683,127,647.08, compared to CNY 623,123,440.86 in the same period of 2023, reflecting an increase of about 10%[109]. - Cash inflow from investment activities totaled CNY 9,630,784,717.99, significantly higher than CNY 1,998,860,233.00 in the previous year, indicating an increase of over 382%[109]. - The net cash flow from investment activities was CNY 727,680,946.95, compared to a negative cash flow of CNY 121,876,520.01 in the same period last year, showing a substantial turnaround[109]. Market Position and Product Development - The company maintained its leading position in the domestic influenza vaccine market, with annual batch issuance of influenza vaccines reaching 2,315.3 million doses in 2020[16]. - The company achieved a 1900% increase in the issuance of quadrivalent influenza vaccines, from 3 batches in the previous year to 60 batches in the current period[16]. - The company has established a production capacity of 100 million doses of quadrivalent influenza vaccine annually, supported by 6 production workshops[18]. - The company is advancing its pipeline with the expected production application for the A and C group meningococcal conjugate vaccine in 2025[17]. - The company is actively developing an mRNA vaccine research platform to prepare for future vaccine innovations[19]. - The company has successfully registered multiple vaccines, including the first quadrivalent influenza vaccine for children in China, filling a market gap[16]. - The company has a diverse product pipeline supported by core technology platforms for vaccine development and production[19]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[1]. - The total amount of raised funds is CNY 227,576.88 million, with CNY 3,190.27 million invested during the reporting period[28]. - As of June 30, 2024, the company has utilized CNY 1,194,069,294.98 of the raised funds, with CNY 1,183,503,598.91 directly invested in committed projects[29]. - The cumulative amount of raised funds that have changed purpose is CNY 36,261.23 million, accounting for 15.93% of the total raised funds[29]. - The company has not changed the investment scale or purpose for the projects, ensuring shareholder interests are maintained[31]. - The total number of shares held by domestic legal persons is 405,000,000, representing 67.38% of the total shares[75]. - The largest shareholder, Hualan Biological Engineering Co., Ltd., holds 67.38% of the shares, totaling 405,000,000 shares[82]. Risks and Challenges - The company faces risks due to a relatively single product structure, with over 90% of revenue coming from flu vaccines, which may impact profitability if market conditions change[43]. - The company faces intensified market competition in the quadrivalent influenza vaccine sector, with potential profit declines due to price reductions by domestic competitors[44]. - The company anticipates that the price adjustment of the quadrivalent influenza vaccine will negatively impact sales revenue, but it believes that lower prices will stimulate market demand and increase vaccination rates in the long term[73]. Compliance and Governance - The company has not faced any administrative penalties or major litigation during the reporting period, indicating a stable operational environment[56][57]. - The company has committed to environmental protection laws and has not reported any pollution incidents or disputes[53]. - The financial statements have been prepared based on the actual transactions and events in accordance with the accounting standards issued by the Ministry of Finance[122]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its ongoing viability[123]. Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[112]. - Future guidance suggests a positive outlook with expected revenue growth of approximately 15% in the next fiscal year[113]. - The company aims to enhance its operational strategies through potential mergers and acquisitions in the future[120].

证券代码：301207 证券简称：华兰疫苗 公告编号：2024-027 3、四价流感病毒裂解疫苗（儿童剂型、预充式 0.25ml/支）调整至 128 元/支。 上述价格均未包含储存运输费，若部分地区收取疫苗储存运输费，挂网价格则 根据储存运输费相应上调。 本次价格调整预计对公司四价流感疫苗销售收入产生不利影响，对公司业绩的 影响最终以公司披露的定期报告为准。从长远来看，价格降低有利于刺激流感疫苗 市场需求的增长，进一步提升流感疫苗接种率，扩大市场规模，带来以价换量的市 场机遇。下一步公司将通过加强内部费用控制，努力提升销量等手段消化降价带来 的压力。敬请广大投资者理性投资，注意投资风险！ 特此公告。 华兰生物疫苗股份有限公司董事会 华兰生物疫苗股份有限公司 关于公司主要产品价格调整的公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为提高流感疫苗的可及性，提升公司产品市场竞争力和市场占有率，减轻人民 群众和政府的经济负担，承担企业社会责任，结合目前市场情况，经华兰生物疫苗 股份有限公司（以下称"公司"）认真研究论证，决定自 2024 年 6 月 5 日起对 ...

华兰生物疫苗股份有限公司 关于2022年限制性股票激励计划首次授予部分 证券代码：301207 证券简称：华兰疫苗 公告编号：2024-025 第一个归属期股票归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 华兰生物疫苗股份有限公司（以下简称"公司"）于2024年4月25日召开第二 届董事会第六次会议和第二届监事会第六次会议，审议通过了《关于公司2022 年限制性股票激励计划首次授予部分第一个归属期归属条件成就的议案》，根 据《华兰生物疫苗股份有限公司2022年限制性股票激励计划（草案修订稿）》 （以下简称"《激励计划》"）的规定，公司2022年限制性股票激励计划（以下 简称"本激励计划"）首次授予的限制性股票第一个归属期归属条件已成就，本 次符合归属条件的激励对象共24人，可归属的限制性股票数量为101.25万股， 占公司总股本的0.17%。近日，公司办理了本激励计划首次授予的限制性股票第 一个归属期归属股份的登记工作，现将相关事项公告如下： 一、2022年限制性股票年限制性股票激励计划实施情况概要 （一）激励计划简 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥34,222,695.90, a decrease of 76.36% compared to ¥144,762,101.26 in the same period last year[4] - Net profit attributable to shareholders was ¥38,589,463.38, down 58.93% from ¥93,967,811.66 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,157,030.81, reflecting a decline of 79.19% compared to ¥68,033,123.18 in the previous year[4] - Basic earnings per share were ¥0.0643, down 72.63% from ¥0.2349 year-on-year[4] - The total operating profit is 43,492,572.96, down from 105,903,077.92, indicating a significant decline in operational performance[26] - The total comprehensive income for the current period is 38,589,463.38, down from 93,967,811.66, a decrease of 58.92%[34] Cash Flow - The net cash flow from operating activities was ¥96,429,081.13, a decrease of 49.92% from ¥192,546,198.76 in the same quarter last year[4] - Cash flow from operating activities netted 96,429,081.13, a decrease of 50.06% from 192,546,198.76 in the previous period[27] - The total cash inflow from operating activities was 494,880,450.31, compared to 475,117,239.77 previously, showing a slight increase of 4.03%[27] - The total cash outflow from operating activities increased to 398,451,369.18, up from 282,571,041.01, reflecting a rise of 41.00%[27] - The net cash flow from investing activities was -111,857,051.36, an improvement from -363,764,238.06 in the previous period, indicating a reduction in cash outflow by approximately 69%[35] - The total cash and cash equivalents at the end of the period amounted to 623,990,420.48, compared to 427,323,825.23 at the end of the previous period, reflecting an increase of about 46%[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,809,176,465.58, a decrease of 2.33% from ¥7,995,318,297.21 at the end of the previous year[4] - The balance of trading financial assets rose to 2,397,529,136.99 from 1,598,524,035.48, marking an increase of 49.97%[31] - The total current assets increased to 5,313,164,810.94 from 5,226,815,305.37, representing a growth of 1.65%[31] - Total liabilities decreased to 1,501,964,758.85 from 1,732,226,370.79, a reduction of 13.29%[62] - Current liabilities decreased to 1,457,039,828.72 from 1,685,582,716.09, a decline of 13.51%[62] Equity and Shareholder Information - The company's total equity attributable to shareholders increased by 0.70% to ¥6,307,211,706.73 from ¥6,263,091,926.42 at the end of the previous year[4] - The total equity attributable to shareholders of the parent company increased to 6,307,211,706.73 from 6,263,091,926.42, marking a growth of approximately 0.7%[48] - The company reported a total of 18,051 common shareholders at the end of the reporting period[43] - The capital reserve increased to 2,920,707,131.72 from 2,915,176,814.79, showing a slight increase of about 0.2%[48] - The company’s retained earnings increased to 2,500,332,943.25 from 2,461,743,479.87, reflecting an increase of about 1.6%[48] Research and Development - The company's R&D expenses decreased by 34.39% to ¥19,022,504.10, down from ¥28,994,998.34 in the previous period[7] - Research and development expenses for the current period are 19,022,504.10, a decrease of 34.12% from 28,994,998.34 in the previous period[63] Other Financial Metrics - The company experienced a 61.41% increase in credit impairment losses, amounting to ¥33,913,652.37, compared to ¥21,010,630.96 in the previous year[7] - The income tax expense for the current period is 4,718,860.68, compared to 11,993,339.14 previously, a reduction of 60.66%[26] - The company reported a net investment income of 16,051,180.00, slightly down from 16,723,286.29 in the previous period[63]

关于作废2022年限制性股票激励计划 部分已授予尚未归属的限制性股票的议案 证券代码：301207 证券简称：华兰疫苗 公告编号：2024-024 华兰生物疫苗股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物疫苗股份有限公司（以下简称"公司"）于2024年4月25日召开第二届 董事会第六次会议和第二届监事会第六次会议，审议通过了《关于作废2022年限制 性股票激励计划部分已授予尚未归属的限制性股票的议案》，现将相关事项公告如 下： 一、2022年限制性股票激励计划已履行的相关审批程序 （一）公司于2022年9月30日召开第一届董事会第十五次会议和第一届监事会 第十五次会议，审议通过了《关于〈华兰生物疫苗股份有限公司2022年限制性股票 激励计划（草案）〉及其摘要的议案》《关于〈华兰生物疫苗股份有限公司2022年 限制性股票激励计划实施考核管理办法〉的议案》《关于提请股东大会授权董事会 办理华兰生物疫苗股份有限公司股权激励计划相关事宜的议案》以及《关于〈华兰 生物疫苗股份有限公司2022年限制性股票激励计划首次授予激励对象名单〉的议 案》。 ...

7879 :;<=>?- | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：华兰疫苗 | | --- | --- | | 保荐代表人姓名：贾鹏 | 联系电话：010-56839300 | | 保荐代表人姓名：刘晓宁 | 联系电话：010-56839300 | @ABCDEFG | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会 ...